A Phase 2/3 Study Investigation the Phamacokinetics, Saf

Project: Research project

Project Details

Description

A Phase 2/3 Study Investigation the Phamacokinetics, Safety and Efficacy of Dupilumab in Patients ages >6 months to <6 years with Severe Atopic Dermatitis
StatusActive
Effective start/end date2/1/172/28/23

Funding

  • Regeneron Pharmaceuticals, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.